Colorectal Neoplasm

Oncology·MeSH: Colorectal Neoplasms, Hereditary Nonpolyposis

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

23 drugs in development·7 companies·1 clinical trial

Drug Pipeline by Phase

Approved(2)

Drug	Company
levoleucovorin	Amneal Pharmaceuticals, Inc. (AMRX)
zaltrap	Sanofi (SNY)

Phase 3(11)

Drug	Company
Amivantamab	REGENXBIO Inc. (RGNX)
Amivantamab	Amneal Pharmaceuticals, Inc. (AMRX)
Amivantamab and Recombinant Human Hyaluronidase	Amneal Pharmaceuticals, Inc. (AMRX)
Camrelizumab and Cetuximab	Amneal Pharmaceuticals, Inc. (AMRX)
Cetuximab	REGENXBIO Inc. (RGNX)
Cetuximab	Amneal Pharmaceuticals, Inc. (AMRX)
Cetuximab	Merck & Co., Inc. (MRK)
Floxuridine	IGM Biosciences, Inc. (IGMS)
folfiri	Sanofi (SNY)
Leucovorin calcium/Levoleucovorin	REGENXBIO Inc. (RGNX)
Tucatinib	PFIZER INC (PFE)

Phase 2(2)

Drug	Company
cetuximab	PFIZER INC (PFE)
tisotumab vedotin	PFIZER INC (PFE)

Phase 1(7)

Phase 4(1)

Drug	Company
Xeloda	IGM Biosciences, Inc. (IGMS)

BioSniper tracks 23 drugs in development for Colorectal Neoplasm across 7 companies.

There are 1 clinical trial targeting Colorectal Neoplasm tracked by BioSniper.

The estimated prevalence of Colorectal Neoplasm is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.